Inhibition of adjuvant-induced arthritis by 16 alpha-fluoro-5-androsten-17-one.
The adrenal steroid dehydroepiandrosterone (DHEA) produces cancer-preventive, antiatherosclerotic, antidiabetic, immunomodulating, and anti-inflammatory effects in laboratory animals. The clinical use of DHEA is limited by its androgenicity. We have developed a synthetic congener of DHEA called fluasterone that, in animal tests, lacks the androgenicity, estrogenicity, and peroxisome-proliferating effects of DHEA but retains the cancer-preventive, antidiabetic, and anti-inflammatory efficacy. This report discusses how fluasterone ameliorates the development of joint inflammation in an adjuvant-arthritis model in Lewis rats.
Schwartz
Arthur G
AG
Fels Institute for Cancer Research and Molecular Biology, Temple University School of Medicine, 3307 North Broad Street, Philadelphia, PA 19140, USA.
Pashko
Laura L
LL
D000818:Animals; D000970:Antineoplastic Agents / Q000494:pharmacology*; D001169:Arthritis, Experimental / Q000188:drug therapy*; D003687:Dehydroepiandrosterone / Q000031:analogs & derivatives* / Q000494:pharmacology*; D005260:Female; D051381:Rats; D011917:Rats, Inbred Lew
D000970:Antineoplastic Agents; D003687:Dehydroepiandrosterone; C106219:5-androstene-16-fluoro-17-one